Merck gets new hearing in Indian fight over generic Januvia; Sandoz rolls out new supplies of scarce TB drug;

@FiercePharma: Roche's Avastin delivered in the first quarter, too: 11% growth, to 1.53B francs, almost back to 2010 levels. | Follow @FiercePharma

@EricPFierce: FDA did 813 inspections in 62 countries last year, but it says it needs even more money to keep up. Story | Follow @EricPFierce

> The Delhi High Court will hear Merck's ($MRK) appeal Friday in a fight over Glenmark Pharmaceuticals' generic versions of the U.S. company's patented diabetes treatments Januvia and Janumet. Report

> U.K. cost-effectiveness watchdogs gave a thumbs-up to Novartis' ($NVS) eye drug Lucentis for an additional use in macular edema patients. Report

> Sandoz has upped its supply of the tuberculosis drug isoniazid, helping to ease a shortage of the drug, which has been scarce since last year. Report

> The new avian flu strain H7N9 has a mutation that causes resistance to Tamiflu, the Roche ($RHHBY) antiviral stockpiled by many governments in case of influenza pandemic; WHO says tests so far haven't turned up resistance to the drug. Report

> Bayer sued the FDA to block a generic version of its livestock antibiotic Baytril from rival drugmaker Norbrook Laboratories, citing worries about off-label use. Report

> Eisai has developed sliding-scale pricing on its Halaven breast cancer drug for its launch in India this fall. Report (sub. req.)

Medical Device News

@FierceMedDev: New radiation therapy companion Dx in the works. More | Follow @FierceMedDev

@MarkHFierce: Roche's diagnostics division sales fell flat in Q1. Dx tests sold well, but its diabetes arm tanked. Story | Follow @MarkHFierce

 @DamianFierce: We read the FDA's budget request so you don't have to: The agency wants an 11% raise for device approvals. Article | Follow @DamianFierce

> FDA slaps most serious label on Stryker's surgical recall. Article

> Doctor accused of performing unnecessary stent procedures begins civil trial. Item

Biotech News

@FierceBiotech: Still trending: Analysts rank the top 10 blockbuster duds in biopharma. Article | Follow @FierceBiotech

@JohnCFierce: Everywhere in the world Big Pharma cuts pretty much as it pleases. Sanofi in France? No way. No how. WSJ Report | Follow @JohnCFierce.

@RyanMFierce: In case you missed last night: J&J, Roche and others back platform to bolster translational drug research. Article | Follow @RyanMFierce

> Omthera discounts IPO shares, prices at $8. Item

> NEA, Pfizer build a launch pad for a portfolio of orphan-drug biotechs. News

> GlaxoSmithKline stakes a pioneering effort to launch 'electroceutical' R&D. Report

> Bristol-Myers maps $250M manufacturing expansion to support growing R&D effort. Story

Pharma Manufacturing News

> FDA nails Pfizer plant for contaminated Torisel diluent. News

> Sanofi plant ramps up malaria treatment with cutting-edge technology. Article

> FDA budget would expand China office. Story

> Hamburg to face Congress again over compounding lapses. Report

> Mylan Napa plant to close by year-end. Article

Vaccines News

> U.S. works with Inovio in prep for bioterrorism vaccinations. Article

> China expects H7N9 vaccine in 7 months. Item

> Ovarian cancer vax makes good start on long slog to approval. Story

> Negative vaccine views spread like viruses on Twitter. Article

> H7N9 an early test for revised U.S. pandemic preparations. Report

And Finally... The share of Americans who get healthcare benefits from their employers dropped to 60% in 2011, 12 million fewer people than in 2000. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.